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Abstract 
 
The need for MRI contrast agents with improved relaxivity maintains the development 
of new Gd(III) chelates an intensive and demanding field of research. In this work we 
introduce the new dimeric chelators bis(DOTA-AHA)adipate and bis(DOTA-AHA)1,3-
phenyldiacetate  (L2 = bis(1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoic)-
4,7,10-triacetic acid)adipate and L3 = bis(1,4,7,10-tetraazacyclododecane-1-((6-
amino)hexanoic)-4,7,10-triacetic acid)1,3-phenyldiacetate, respectively), based on the 
bifunctional ligand DOTA-AHA (L1 = 1,4,7,10-tetraazacyclododecane-1-((6-
amino)hexanoic)-4,7,10-triacetic acid). Their Gd(III) chelates were studied by variable 
temperature 1H NMRD and 17O NMR spectroscopy in order to measure the relaxivity 
and the parameters that govern it. The exchange of inner-sphere water from the 
monomer GdL1 and from the two binuclear chelates Gd2L2 and Gd2L3 is very similar 
(298kex ≈ 6.5 x106 s-1) and slightly faster than on [Gd(DOTA)H2O]- (298kex = 4.1 x 106 s-
1). All three compounds form weakly bound aggregates with equilibrium constants 298K 
of 2.9, 15.6 and 14.6 for GdL1, Gd2L2 and Gd2L3, respectively. Even if the aggregates 
contain only 10 to 15% of the total amount of Gd(III) ions a marked increase in 
relaxivity between 30 and 100 MHz is observed. 
Furthermore the distance between the two Gd(III) centers in the binuclear compounds 
has been determined by double electron-electron resonance (DEER) experiments and by 
molecular modelling studies affording comparable distances. The linkers between the 
chelating moieties allow Gd(III)-Gd(III) distances of circa 3.0 nm for completely 
stretched linker conformation and ≤ 1.9 nm for the conformation with the metal centers 
at closer distance. These metal to metal distances by themselves cannot explain the 
considerably long tumbling times of chelates in solution. Only a model consistent with 
some level of aggregation for the binuclear chelates in aqueous solution could 
satisfactorily explain our results. 
 
Introduction 
 
Magnetic resonance imaging (MRI) has become one of the most powerful and useful 
techniques in medicine for soft tissue imaging. This imaging technique is based on the 
interaction of magnetic fields and radiofrequencies with the water molecules of the 
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body.[1] The quality of a MRI scan depends on intrinsic  properties  of the biological 
tissues such as the density (H) of the hydrogen nuclei, the blood flow and the hydrogen 
nuclei relaxation times (T1 and T2).
[2] However, soft tissues have little difference in 
proton density (not more than 10%) and consequently image intensity often displays 
low contrast.[1] In such cases there is the need of contrast agents (CAs) to further 
enhance the contrast between the tissues. These CAs are paramagnetic compounds 
which shorten the relaxation times of local proton spins (T1 and T2), increasing the 
signal intensity on T1 weighted images and decreasing it on T2 weighted images.
[3] 
The majority of the approved CAs are gadolinium chelates based both on macrocyclic 
tetraazapolyaminocarboxylate chelators (ex: Dotarem®, Prohance® or Gadovist®) and 
open-chain polyaminocarboxylate chelators (ex: Magnevist®, Omniscan® or 
Multihance®). These low molecular weight chelates constitute the first generation of 
MRI contrast agents and are extracellular fluid agents since they equilibrate rapidly 
between the intravascular and interstitial space and do not interact specifically with any 
type of cells.[4] The effectiveness of any contrast agent is measured by its relaxivity (r), 
which is the enhancement of the water protons relaxation rate imposed by a 1 mM 
concentration of Gd(III) chelate.[5] The development of low molecular weight CAs with 
enhanced relaxivities is highly desirable and several small Gd(III) chelates have been 
reported over the past years.[6] 
There are several approaches to increase the relaxivity through the optimization of its 
molecular parameters. The rotational correlation time (R), water exchange rate (kex) and 
electron spin relaxation times (Te) are the most important parameters determining 
relaxivity. Because Te is mainly dependent on the metal ion it is not easily changeable, 
but the other two parameters can be tuned by ligand design.[5] However, the 
optimization of both parameters via chelator design is challenging and demanding.[7] 
The development of molecular constructs containing several gadolinium units is a 
strategy that has been applied often. It relies on the formation of multinuclear 
assemblies, either through covalently bound chelates such as multimeric structures,[8] 
linear polymeric structures[8d, 9] or spherical dendrimers;[10] or non-covalently bound 
chelates such as micelles,[11] liposomes,[11c, 12] or even metal ion-assisted aggregation of 
gadolinium chelates.[13] All these molecular constructs present longer rotational 
correlational times. To tune this parameter seems to be the most simple and 
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straightforward choice, since R values have a direct correlation with the weight and size 
of the chelate.[14] 
Chemical modifications in the chelating moiety should not interfere with the ability to 
retain Gd(III), since it has been reported severe toxicity associated with repeated CAs in 
individuals suffering from kidney function impairment.[15] The design of new 
gadolinium chelates that ensure the patient’s safety associated with the possibility of 
relaxivity improvement has become the prime goal in the development of new CAs, and 
it favors the use of macrocyclic DOTA-type ligands.[16] Over the past years, several 
bifunctional DOTA-based chelators bearing extra functional groups in one acetate arm 
have been reported in the literature.[17] The extra functional group in the pendant arm 
allows the binding of the Gd(III) chelate to a plethora of chemical moieties through 
different linkages without reducing the thermodynamic stability and kinetic inertness. 
Accordingly, in the first part of this paper we report the synthesis of a new bifunctional 
chelator, 1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoic)-4,7,10-triacetic acid 
(DOTA-AHA) (Figure 1 – L1). Although its gadolinium chelate Gd(DOTA-AHA) may 
be considered a candidate for contrast agent, it is nevertheless more promising as a 
building block for multinuclear chelates of concomitant higher relaxivities. 
 
 
Figure 1. DOTA-AHA (L1) bifunctional ligand. 
 
Despite showing improvement in relaxivity, large Gd(III)-containing molecular 
constructs also show some drawbacks. Their elevated size is responsible for the slow 
leakage from blood vessels to interstitial space through the normal endothelium of 
vascular systems.[4] This phenomenon provides long imaging windows, but limits their 
applicability. Their pharmacokinetic profile is also a concern, since these molecules 
may also be important “targets” for enzymatic systems, which may result in undesired 
metabolization. Moreover, problems with the excretion of these macromolecular Gd(III) 
agents are recurrent, since the glomerular filtration can decrease drastically.[18] 
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Alternatively, dimerization can be a straightforward way to obtain CAs with improved 
relaxivity, without drastically increasing the molecular weight and size.[14, 19] Several 
DO3A-based binuclear Gd(III)[20] (Scheme 1 – A to F) and other Ln(III)[21] chelates are 
found in the literature. Overall, the gadolinium chelates present improved relaxivity per 
metal ion in comparison to Gd(DOTA)-, due to optimization of the rotational 
correlational time. Simultaneously, the dimerization of these Gd(DO3A)-based chelates 
leads to neutral charged complexes opposing to the electrocharged monomers from 
which they were synthesized. Negatively charged chelates show higher 298kex values 
than the corresponding electroneutral ones.[6b] Therefore, the relaxivity values 
potentially achievable by chelates displaying relatively long R values are not reached 
due to the limited water exchange rates of these electroneutral Gd(DO3A)-binuclear 
chelates. To overcome this downside, we synthesized two DOTA-AHA-based dimeric 
ligands, the bis(1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoic)-4,7,10-triacetic 
acid)adipate (bis(DOTA-AHA)adipate) and the bis(1,4,7,10-tetraazacyclododecane-1-
((6-amino)hexanoic)-4,7,10-triacetic acid)1,3-phenyldiacetate (bis(DOTA-AHA)1,3-
phenyldiacetate) (Scheme 1 – L2 and L3). Their Gd(III) chelates have been studied by 
1H NMRD, 17ONMR and EPR and the results obtained are reported in this paper. 
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Scheme 1. DO3A and DOTA-based dimeric ligands for Gd(III). The DO3A ligands have been reported in 
the literature.[20] 
 
Results and Discussion 
 
Synthesis 
The DOTA-AHA chelator was prepared from a lysine precursor using orthogonal 
protecting groups (scheme 2). The dimeric DOTA-AHA derivatives were obtained by 
reacting two dicarboxylic acids (adipic acid and 1,3-phenyldiacetic acid) with 
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compound 5 (scheme 3). After deprotection, the dimeric ligands bis(1,4,7,10-
tetraazacyclododecane-1-((6-amino)hexanoic)-4,7,10-triacetic acid)adipate (bis(DOTA-
AHA)adipate) and bis(1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoic)-4,7,10-
triacetic acid)1,3-phenyldiacetate (bis(DOTA-AHA)1,3-phenyldiacetate)) were isolated. 
 
 
Scheme 2. Synthetic pathway of DOTA-AHA chelator (L1). a) NaBr, NaNO2, HBr (1 M); b) DDM, 
Me2CO; c) Cyclen, K2CO3, MeCN; d) tert-butyl bromoacetate, K2CO3, MeCN; e) Pd(PPh3)4, 
Me2NH.BH3, DCM; f) TFA, DCM. 
 
 
Scheme 3. Synthetic scheme of DOTA-AHA dimers. a) adipic acid (6) or 1,3-phenyldiacetic acid (7), 
DIPEA, HATU, HOBt, MeCN; b) TFA, DCM. 
 
1H NMRD and 17O NMR Relaxometric Studies 
To obtain parameters characterizing the efficiency in view of water relaxation 
enhancement of the mononuclear compound GdL1, as well as the binuclear compounds 
Gd2L2 and Gd2L3, 
1H NMRD profiles and 17O relaxation and chemical shift 
measurements have been performed (Figure 2). From the experimental NMRD data it 
can be seen that the two binuclear compounds clearly show a relaxivity hump between 
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20 and 120 MHz whereas the relaxivity profile of the mononuclear compound is rather 
flat (Figure 2c). The reduced transverse 17O relaxation, 1/T2r, is very similar for the 
three compounds over the whole temperature range studied (Figure 2a), indicating that 
water exchange should be similar. The reduced longitudinal 17O relaxation, 1/T1r, is also 
similar which would indicate that the rotational motion of the mononuclear and 
binuclear compounds do not differ significantly. Apparently this is in contradiction to 
the NMRD data. 
 
Figure 2. (a) - Reduced transverse (squares) and longitudinal (circles) 17O NMR relaxation rates for GdL1 
(20 mM [Gd(III)] (red), Gd2L2 (black) (12 mM [Gd(III)]) and Gd2L3 (blue) (12 mM [Gd(III)]); (b) 
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Reduced 17O chemical shifts for GdL1 (), Gd2L2 () and Gd2L3 (); (c) 1H NMRD profiles for GdL1 
(red), Gd2L2 (black) and Gd2L3 (blue) at 25 ºC () and 37 ºC (). The lines represent the best fit of the 
data resulting from simultaneous fitting based on SBM equations. 
 
We assumed that standard Solomon-Bloembergen-Theory (SBM)[3-4] is valid in our case 
(see reference [7, 22] for a comparison of different theoretical approaches). The 1H 
NMRD and 17O NMR data have been evaluated using a simultaneous fitting 
procedure.[20b] This procedure is the most efficient way to get reliable parameters 
characterizing the relaxation properties of gadolinium complexes in solution: 
 water exchange (kex, ΔH‡) is best obtained from temperature dependent 
transverse 17O relaxation (/1/T2r); the scalar coupling constant (A/ħ) entering this 
data can be obtained from 17O NMR chemical shift 
 rotational correlation times (R) are obtained from frequency dependent 
longitudinal 1H relaxation (r1, NMRD) and from temperature dependent 
longitudinal 17O NMR relaxation (1/T1r) 
The information on the dynamics of the paramagnetic complexes is obtained by 
relaxation enhancement measured on bulk water molecules to which it has been 
transmitted by chemical exchange. It is not known per se if there is only one 
exchanging species present or if there are several with different rotational behavior. 
A first attempt showed that the 1H NMRD and 17O NMR data could not be fitted 
satisfactorily using a single rotational correlation time (see Supporting Information). A 
satisfactory fit of the data could be obtained using two correlation times – a short one 
(R, < 200 ps) and a long one (R, > 2000 ps). In the case of Gd-complexes in solution 
there are two possible scenarios: 
1. Most of the gadolinium complexes aggregate. The rotational diffusion of the Gd-H 
vectors can be described by the global reorientation of the aggregate (global 
correlation time g) and by possible local motions (local correlation time l). The 
theoretical description follows the Lipari-Szabo model developed for the dynamics 
of proteins.[23] The way the Gd-H vectors sense both motions is described by a 
model-free order parameter S. 
2. Some gadolinium complexes aggregate but some are still present as single 
compounds. The rotational motion of the single compounds (monomers) is 
characterized by R
mono and the rotational motion of the aggregates by R
agg. 
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To check for aggregation of the compounds we measured 1H relaxivity as a function of 
concentration - in absence of aggregation the relaxivity, r1, should not depend on 
[Gd(III)]. The results show that for both binuclear chelates r1 increases by more than 
50% if the concentration of the paramagnetic ion is raised from 0.1 mM to about 12 mM 
(Figure 3). This increase is less than, for example, that observed for the trinuclear 
Gd3Ph4(DTTA)3
[24] and it also starts at much higher concentration, 4 mM in contrast to 
0.1 mM. The relaxivity of Gd2L2 and Gd2L3 measured at low concentration is close to 
that of the mononuclear compound GdL1. These data suggest that the binuclear 
compounds weakly aggregate. This finding is remarkable; first, there is no hydrophobic 
linker between the two chelates and second, the Gd(DOTA)-chelates are charged and 
not neutral like the Gd(DO3A)-type chelates. 
 
 
Figure 3. Concentration dependent relaxivity of the binuclear Gd2L2 (□) and Gd2L3 () measured at 1.41 
T (60 MHz) and 37 °C. 
 
The Lipari-Szabo model has been used to describe rotational diffusion of different kinds 
of compounds like dendrimers, polymers, micelles and aggregates. As far as we know 
the second scenario with weakly self-aggregating monomers has not yet been applied in 
the context of paramagnetic compounds forming weakly bound aggregates and 
exchanging water molecules with the bulk. To be able to treat the data with a reasonable 
number of parameters some assumptions have to be made: 
First, the water exchange between the first coordination sphere and bulk does not 
change when the compounds form aggregates. This assumption is very reasonable 
because it has been shown that water exchange does not change markedly if binuclear 
compounds are formed using the same chelator.[25] 
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The second assumption is that all equilibrium constants for forming dimers, 
trimers, tetramers, etc. from the same monomer are equal. If we name the monomer A 
we have[26] 
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The total amount of compound A in solution is given by[27] 
 
         
 
2 30
2 2 3 1
2
2 3 ... n
[ ] 2 [ ] 3 [ ] ... [ ]
[ ]
1 [ ]
n
n n
A A A A A
A K A K A nK A
A
K A

    
    


 (3) 
 
The temperature dependence of the equilibrium constant is 
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If the binding between the aggregate forming monomers is relatively weak we can 
assume that the rates of formation and dissociation of the aggregates are fast compared 
to the rate of water exchange. In this case we can calculate the enhancement of 
longitudinal relaxation 1/T1r as  
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where xi are the mole fractions of Gd
3+ in the monomer (1), dimer (2), etc and <T1m> is 
the weighted mean of the longitudinal relaxation rate of bound water spins. The mole 
fractions can be calculated from the equilibrium constants via the roots of equation 3. 
The relaxation rates of bound water molecules, 1/T1m,i in the different aggregates differ 
only by the rotational correlation times. Clearly, we should have R,1 < R,2 < R,3 < etc. 
To keep the number of fitted parameters reasonable we used only two correlation times, 
that for the rotation of the monomer, R,1 = R
mono, and a mean correlation time for the 
rotation of aggregates <R,i> = R
agg. As a test we fitted the data of the binuclear 
compound Gd2L3 with three correlations times. The quality of the fit did not increase 
markedly and besides the correlation times all other parameters of the fits were 
unchanged (see Supporting Information). 
Inspection of the equations resulting from the two scenarios described above shows that 
the theoretical descriptions are nearly equal with the main difference that the Lipari-
Szabo order free parameter S2 is replaced by the mole fraction of Gd(III) present in the 
aggregates. In contrast to S2 the mole fraction depends on temperature leading to an 
increased quality of the fit (for details see Supporting Information). Consequently we 
fitted the three data sets using the self-aggregation model (Figure 2). 
As can be seen from the results in Table 1 water exchange rate constants at room 
temperature, 298kex, are equal within experimental error. This is not surprising because 
all compounds use the same chelating unit to bind Gd(III). The rate constants at 298 K 
are slightly higher than that of [Gd(DOTA)]- (298kex = 4.1 10
6 s-1) but about four times 
faster than that of the DO3A based dimers [bisoxa[(Gd(DO3A)]2] and 
[pip[(Gd(DO3A)]2] (
298kex = 1.4 10
6 s-1 and 298kex = 1.5 10
6 s-1, respectively). The 
increase in lability is most probably due to the negative charge of the DOTA 
compounds.[6b] From the positive entropies of activation, S‡, one can conclude that the 
mechanism has a more dissociative character than on DO3A-type complexes (S‡, = 
+1.7 and -11.7 J K-1 mol-1). 
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Table 1. Water exchange parameters, 298kex, H‡, S‡, rotational correlation times, 298Rmono, 298Ragg, and equilibrium constants, K298, H0,S0 , for aggregation GdL1, Gd2L2 and 
Gd2L3. The parameters were obtained from a simultaneous fit of 17O NMR and 1H NMRD data using SBM theory. 
a) mole fraction of the monomer; b) at [GdL1] = 20 mM; c) at [Gd2L2/3] = 6 mM 
 
 
Table 2. Distribution of gadolinium in monomers, dimers and trimers calculated from K298 and equation 3 at 298K. 
 
 
 
 
 
 
 
 
298kex 
(106 s-1) 
H‡ 
(kJ mol-1) 
S‡ 
(J K-1 mol-1) 
298Rmono 
(ps) 
298Ragg 
(ps) 
H0 
(kJ mol-1) 
S0 
(kJ mol-1) 
K298 
(M-1) 
x1a) 
Mononuclear          
GdL1 6.4 ± 1.4 58 ± 7 +81 ± 23 103 ± 13 2600 ± 2100 -41 ± 19 -129 ± 63 2.9 0.90b) 
Binuclear          
Gd2L2 6.8 ± 3 54 ± 8 +68 ± 30 129 ± 10 4000 ± 1800 -32 ± 9 -84 ± 31 15.6 0.85c) 
Gd2L3 6.4 ± 1.1 63 ± 5 +95 ± 18 134 ± 7 4000 ± 1200 -33 ± 6 -89 ± 20 14.6 0.86c) 
 [Gd3+] K298 (M-1) monomer dimer trimer 
Mononuclear      
GdL1 20 mM 2.9 89.9 % 9.4 % 0.7 % 
Binuclear      
Gd2L2 12 mM 15.6 84.8 % 13.4 % 1.6 
Gd2L3 12 mM 14.6 85.6% 12.8 % 1.4 
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All complexes, the mononuclear GdL1 as well as the binuclear Gd2L3 and Gd2L3 form 
aggregates in solution. For GdL1 the constant for complex formation K298 is 5 to 6 times 
smaller than for the binuclear complexes (Table 1). From the equilibrium constants we 
can calculate the relative amounts of Gd(III) ions as monomer, dimer or trimer (Table 
2). For the mononuclear species dimers are present only in a small amount (≈ 10 %). 
For both binuclear species the amount of Gd(III) present in an aggregate is ≈ 15 % and 
the major aggregated form is again the dimer. The intermolecular interaction leading to 
aggregation is much weaker between our compounds if compared to DO3A based 
binuclear compounds.[28] The seven-coordinating DO3A chelator allows formation of 
carboxylate bridges and leads therefore to very stable aggregates. 
From the point of view of water proton relaxivity the compounds in its monomeric or 
aggregated form are characterized by the rotational correlation times τRmono and τRagg, 
respectively. The values obtained by the fitting differ for all three compounds by more 
than one order of magnitude (Table 1). Surprisingly the 298τRmono value fitted for the 
mononuclear compound is only 25% shorter than the corresponding values of the 
binuclear compounds. A possible explanation could be a high degree of internal rotation 
in both binuclear compounds. The longer value of 298τRmono of GdL1 in respect to for 
example Gd(DOTA) can be explained by the C5NH2-chain attached to the ligand. The 
298τRmono of the binuclear Gd2L2 and Gd2L3 are in the same order as those of other 
binuclear compounds (Gd2(bisoxa(DO3A)2): 106 ps,
[20b] Gd2(pip(DO3A)2): 171 p,
[20b] 
Gd2(DOPTA): 200 ps,
[8a] Gd2CS(DO3A-PNBn)2: 183 ps,
[8c] Gd2bipy(DO3A)2: 185 
ps.[28b] 
A rotational correlation time 298τRmono of “only” ~130 ps can be explained by the rod-
like shape of the binuclear compounds (Figure 4 and Figure 6). The rotational motion 
sensed by the Gd-H vector is probably close to the rotation around the Gd-Gd axis 
(Figure 4); rotation around an axis perpendicular to the Gd-Gd axis would lead to much 
slower 298τRmono.  
 
Figure 4. Anisotropic rotation of binuclear compounds. 
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The rotational correlation times for the aggregates are 298τRagg ≈ 2.6 ns for GdL1 and ≈ 4 
ns for the binuclear compounds with relatively big statistical errors. The increase by 
more than a factor of twenty from a monomer to essentially a dimer seems to be quite 
substantial. An effective molecular radius of the aggregates can be estimated to reff. ≈ 
1.5 nm using the Debye-Stokes equation (equation 7). Such a radius is fully compatible 
with the elongated molecular mechanics structures (see below). The strong increase 
from 298τRmono ≈ 0.13 ns to 298τRagg ≈ 4 ns can therefore be explained by the anisotropic 
rotation of the monomer with rGdH sensing the fast motion and the more isotropic 
rotation of the aggregates with rGdH sensing the slow overall motion. This explanation 
implies the absence of fast internal motion in the aggregates (for more detailed 
information see Supporting Information).  
 
34
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The NMR relaxation results clearly show that the binuclear but also the mononuclear 
compounds form weak aggregates in solution. Only 15 % in the binuclear compounds 
and 10 % in the mononuclear compound of the total amount of Gd(III) is present in 
aggregates. This is however enough to influence markedly the NMRD profiles (Figure 
5c). 
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Figure 5. Influence of aggregation of Gd2L3 on 17O NMR and 1H NMRD: blue full curves calculated with 
parameters in Table 1; green dashed curves calculated with 100% monomer. (a) 17O 1/T2r (□) and 1/T1r 
(○); (b) 17O Δωr (); (c) 1H NMRD at 25 ºC () and 37 ºC (). 
 
The relaxivities of the binuclear compounds Gd2L2 and Gd2L3 are about 50% higher 
than that of the mononuclear GdL1: at 60 MHz and 37 °C the relaxivities of Gd2L2 and 
Gd2L3 are r1 = 7.3 mM
-1s-1 and r1 = 7.1 mM
-1s-1 respectively, and GdL1 has r1 = 4.7 
mM-1s-1. The relaxivity of the mononuclear compound is slightly higher than that of 
Gd(DOTA) (r1 = 3.1 mM
-1s-1 at 60 MHz, 37 °C[29]) which is mainly due to the 10 % of 
aggregates formed. Without aggregates one can calculate a relaxivity of 3.7 mM-1s-1 at 
37 °C and 60 MHz. The remaining small increase is due to the C4 chain attached to the 
chelate. 
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DEER and Modelling Studies 
Distributions of GdGd distances for the binuclear chelates were measured with double 
electron-electron resonance (DEER) technique.[30] This pulse EPR technique allows 
detecting static magnetic dipolar interaction in the pairs of paramagnetic centers, which 
is then recalculated into the distance distribution. Currently, most applications of DEER 
technique[31] are found in the field of structural biology in combination with site-
directed spin labeling,[32] but the technique is generally applicable to any large 
molecules possessing paramagnetic centers with nanometer-range distances between 
them. While most DEER experiments are done with pairs of nitroxide radicals, over the 
last seven years gadolinium chelates were proved to be a possible alternative type of 
spin centers for DEER measurements.[33] 
We performed Gd-Gd DEER measurements on both Gd2L2 and Gd2L3 chelates, in 
order to determine the distribution of distances between the two Gd(III) centers and try 
to understand if the distances may have influence on the binuclear compounds 
relaxivity. The DEER experiment is done in a frozen glassy state, and thus can be 
considered as a static snap-shot of the dynamic ensemble of conformations present in 
solution. The measured distance distribution is, however, limited to the inter-spin 
distances above approximately 1.3 nm due to the bandwidth limitation of the microwave 
pulses. The upper limit of the detectable distances is set by the transverse relaxation 
time of the paramagnetic centers, and this limit was well beyond the longest detected 
distances in our experiments.[34] 
The longest Gd-Gd distances present in the samples were about 2.7 nm for Gd2L2 and 
about 3 nm for Gd2L3 (See Supporting Information). In both cases the fitted distance 
distributions appeared broad and covered the whole range of distances from the 
corresponding upper distance value down to the shortest detectable distance. Neither for 
Gd2L2 nor for Gd2L3 could the intra-molecular DEER form factors be perfectly fitted 
by the standard routines of DeerAnalysis[35] package, suggesting the presence of some 
Gd-Gd distances below the detection limit. Such short distances are known to cause 
fitting deviations. Still, an estimate of the fraction of such short distances in the 
statistical ensemble is very difficult in the present case. Typically the fraction of 
detected spin pairs is estimated from the depth of dipolar oscillations in the DEER time 
trace. For short Gd-Gd distances, however, other effects, such as interference with 
strong pseudo-secular term in the dipolar spin-Hamiltonian, were claimed to influence 
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DEER modulation depth, example given by a bis-Gd compound, similar to the ones 
studied in this work.[36] We can thus conclude that DEER measurements are in line with 
the flexible molecular structure of the studied compounds, and that these measurements 
would not contradict the presence of shorter Gd-Gd distances, originating, for instance, 
from some degree of aggregation (as no molecular conformations with Gd-Gd distances 
below 1.3 nm were predicted by modeling, see below). The estimate of the possible 
degree of aggregation could not be unambiguously done from the given EPR data. 
Molecular modelling using MM3 force field in vacuum afforded Gd-Gd distances for 
Gd2L2 and Gd2L3 (Figure 6) which are in good agreement with the DEER results. The 
distances reported for each compound are the longest and the shortest distance from 
short molecular dynamics sampling. The linker is the only feature that distinguishes the 
two chelates. 1,3-phenyldiacetate is a lengthier linker than adipate so, the small 
difference found in the Gd-Gd distances for completely stretched conformation was 
predictable. The slightly longer rotational correlation time of the monomeric Gd2L3 also 
reflects its lengthier linker. 
 
 
Figure 6. Molecular mechanics structures (MM3 force field) illustrating possible conformations of Gd2L2 
and Gd2L3 and Gd-Gd distances. 
 
Conclusion 
 
In this work, we developed a synthetic route for the synthesis of DOTA-AHA (L1), a 
novel DOTA-based bifunctional chelator for trivalent gadolinium, and its derivatives 
Bis(DOTA-AHA)adipate (L2) and Bis(DOTA-AHA)1,3-phenyldiacetate) (L3). The 
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relaxometric properties of their Gd(III) chelates could only be understood on the basis 
of a model that envisages the formation of aggregates in solution. 
The chelate Gd(DOTA-AHA) (GdL1) has a slightly faster water exchange than 
Gd(DOTA)- but its higher relaxivity is due to the existence of circa 10% of Gd((III) in 
the aggregated form, besides to the lateral pendant C4-NH2 chain. The binuclear 
derivatives [Gd2(Bis(DOTA-AHA)adipate)]
2- (Gd2L2) and [Gd2(Bis(DOTA-AHA)1,3-
phenyldiacetate)]2- (Gd2L3) do not show a considerable relaxivity improvement in 
comparison to other existing DO3A-based binuclear Gd(III) chelates for lower 
frequencies (20 MHz), despite the higher water exchange rates on DOTA based chelates 
in comparison to DO3A based chelates. However, these binuclear chelates show a 
considerable augment in relaxivity as the frequency increases, surpassing other Gd(III) 
binuclear constructs at the frequencies with relevance for MRI scans (between 50 and 
100 MHz). This augment in relaxivity has also been attributed to aggregation of the 
chelates (with approximately 15% of Gd(III) in the aggregated form). 
For the binuclear chelates, DEER and modelling studies afforded the distances of 
maximum and minimum approach of the two Gd(III) centers in a very reasonable 
agreement, consistent with the assumption that chelates of such dimensions by 
themselves, without aggregation, would not present such high relaxivities. 
 
Experimental 
 
Chemicals and Materials 
Analytical grade solvents were used and dried by the usual methods when was needed. 
Analytical grade reagents were purchased from Sigma-Aldrich, Acros, Bachem, Merck, 
Chematech and used without further purification. 17O-enriched water was purchased 
from IsoTrade GmbH (Mönchengladbach, Germany). 
The reactions were monitored by thin layer chromatography (TLC) on glass plates 
coated with silica gel 60 F254 (Whatman) and detection was made by examination under 
UV light (240 nm), by adsorption of iodine vapor and/or by spraying with ninhydrin. 
Chromatographic separations were performed on silica gel 60 (Whatman 230-240 
Mesh). 
 
Instruments 
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The 1H and 13C NMR spectra (assigned by DEPT, HSQC and HMBC techniques) were 
recorded on a Bruker Avance III 400 spectrometer, operating at 400.13 MHz and 100.62 
MHz, for 1H and 13C NMR respectively. The chemical shifts () are reported in ppm, 
relative to TMS (tetramethylsilane) for CDCl3 solvent (
1H, =7.26; 13C, =77.16) or 
DMSO solvent (1H, =2.50; 13C, =39.52), and relative to TSP (3-
(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt) for D2O solvent (
1H, =4.79).[37] 
The high resolution mass spectra (HRMS) were recorded on a VG Autospec M 
spectrometer. The pH measurements were performed on a pH meter Crison micro TT 
2050 with an electrode Mettler Toledo InLab 422. 
The proton longitudinal relaxation rates (1/T1) for the water nuclear magnetic relaxation 
dispersion profiles (NMRD) were measured using the following equipment: Bruker 
minispecs mq20 0.47 T (1H Larmor frequency: 20 MHz); mq30 0.70 T (30 MHz); mq40 
0.94 T (40 MHz); and mq60 1.41 T (60 MHz); Bruker Avance console connected to 
2.35 T (100 MHz) and 4.7 T (200 MHz) cryomagnets and Bruker Avance II 9.4 T 
(400 MHz). The temperature was controlled either by a thermostated gas flow 
(cryomagnets) or by pumping a thermostated liquid trough the probe (minispecs). All 
temperatures were measured by substitution technique.[38] The variable-temperature 17O 
measurements were performed on a Bruker Avance II 9.4 T (17O Larmor frequency: 
54.3 MHz) spectrometer, equipped with a Bruker BVT3000 temperature control unit 
and a Bruker BCU05 cooling unit. The susceptibility measurements were performed on 
a Bruker Avance 400 spectrometer, also equipped with a BVT-3000 temperature control 
unit. 
For the EPR experiments, the Gd(III)-Gd(III) distance measurements were performed 
with the 4 pulse DEER experiment[30b, 33a] at Q band on a home-built high microwave 
power spectrometer[39] equipped with a rectangular resonator accommodating for 3 mm 
outer diameter samples.[40] The temperature was set and stabilized with a He-flow 
cryostat Oxford Instruments ER 4118 CF. 
 
Synthesis 
 
6-Amino(Alloc)-2-bromohexanoate benzhydryl ester (compound 1 and 2). 3.965 g 
(11.52 mmol) of Lys(Alloc)-OH and 4.148 g (40.3 mmol) of sodium bromide were 
dissolved in 23.05 mL (23.05 mmol) of 1 M hydrobromic acid and the solution was 
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cooled down in an ice bath. 1.589 g (23.03 mmol) of sodium nitrite were added in small 
portions and the mixture was stirred for 2 hours at 0 °C. 45 mL of water and 105 mL of 
ethyl ether were added to the mixture. The organic phase was collected, and the aqueous 
phase was extracted with 3x35 mL of ethyl ether. The organic phases were combined, 
washed with 3x35 mL of brine, dried with anhydrous MgSO4 and concentrated under 
reduced pressure to give a yellow oil. The oil was dissolved with 90 mL of acetone, 
stirred at 0 °C, and 2.684 g (13.82 mmol) of DDM dissolved in 150 mL of acetone were 
added dropwise over a period of 1 hour. The mixture was stirred for 4 hours at 0 °C and 
over 2 days at room temperature. The solution was concentrated under reduced pressure 
to give a yellow oil. The oil was purified by column chromatography over silica gel 60 
(cyclohexane/ethyl acetate 4:1) to afford 5.301 g (52.3%) of a yellow oil. 1H NMR (400 
MHz, DMSO, TMS, ): 1.16-1.47 (4H, m, -CH2 + -CH2), 1.85-2.08 (2H, m, -CH2), 
2.92 (2H, q, J=6.3Hz, -CH2), 4.43 (2H, d, J=5.6Hz, OCH2(Alloc)), 4.69 (1H, t, 
J=7.2Hz, -CH), 5.14 (1H, dd, J1=10.4Hz, J2=1.6Hz, CH-cis(Alloc)), 5.25 (1H, dd, 
J1=17.2Hz, J2=2.0Hz, CH-trans(Alloc)), 5.83-5.91 (1H, m, CH(Alloc)), 6.83 (1H, s, 
CH(Benzhydryl)), 7.16 (1H, t, J=5.8Hz, RNHR'), 7.26-7.43 (10H, m, CH-
Ph2(Benzhydryl)) ppm. 
13C NMR (100 MHz, DMSO, TMS, ):  23.28 (-CH2), 28.58 
(-CH2), 33.90 (-CH2), 39.86 (-CH2), 46.71 (-CH), 64.09 (OCH2(Alloc)), 77.68 
(CH(Benzhydryl)),  116.81 (CH2(Alloc)), 126.47 (CH-Ph), 127.96 (CH-Ph), 128.55 
(CH-Ph), 133.84 (CH(Alloc)), 139.80 (C-Ph), 155.88 (RCOR'(Alloc)), 168.15 
(RCOR'(Benzhydryl)) ppm. HRMS (ESI+) – m/z: calculated for C23H26BrNO4 (MH+) = 
460.11235, 462.11030, (MNa+) = 482.09429, 484.09224; obtained = 460.11168, 
462.10987 (MH+), 482.09549, 484.09181 (MNa+). 
 
1,4,7,10-Tetraazacyclododecane-1-(6-amino(Alloc)hexanoate benzhydryl  ester) 
(compound 3). 725.8 mg (4.37 mmol) of 1,4,7,10-tetraazacyclododecane were 
dissolved in 70 mL of MeCN and to this solution, 431.7 mg (3.12 mmol) of potassium 
carbonate were added. 1.438 g (3.12 mmol) of 6-amino(Alloc)-2-bromohexanoate 
benzhydryl ester dissolved in 40 mL of MeCN were added dropwise over a period of 2 
hours. The mixture was stirred overnight at room temperature, filtered under vacuum 
and concentrated under reduced pressure to give a yellow oil. The oil was purified by 
column chromatography over silica gel 60 (DCM/EtOH 7:3) to afford 1.608 g (94.2%) 
of a yellow oil. 1H NMR (400 MHz, DMSO, TMS, ): 1.17-1.32 (2H, m, -CH2), 1.33-
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1.51 (2H, m, -CH2), 1.52-1.74 (2H, m, -CH2), 2.52-2.82 (16H, m, 8xCH2(cyclen)), 
2.92-3.02 (2H, m, -CH2), 3.45-3.51 (1H, m, -CH), 4.43 (2H, d, J=5.2Hz, 
OCH2(Alloc)), 5.15 (1H, dd, J1=9.6Hz, J2=2.8Hz, CH-cis(Alloc)), 5.25 (1H, dd, 
J1=17.6Hz, J2=1.6Hz, CH-trans(Alloc)), 5.83-5.93 (1H, m, CH(Alloc)), 6.82 (1H, s, 
CH(Benzhydryl)), 7.16 (1H, t, J=5.4Hz, RNHR'), 7.25-7.45 (10H, m, CH-
Ph2(Benzhydryl)) ppm. 
13C NMR (100 MHz, DMSO, TMS, ):  23.20 (-CH2), 28.90 
(-CH2), 29.12 (-CH2), 40.24 (-CH2), 44.88, 46.36, 47.92, 48.44 (CH2(cyclen)), 64.10 
(OCH2(Alloc)), 64.46 (-CH), 76.70 (CH(Benzhydryl)),  116.86 (CH2(Alloc)), 126.70 
(CH-Ph), 127.80 (CH-Ph), 128.54 (CH-Ph), 133.83 (CH(Alloc)), 140.46 (C-Ph), 155.90 
(RCOR'(Alloc)), 171.81 (RCOR'(Benzhydryl)) ppm. HRMS (ESI+) – m/z: calculated 
for C31H45N5O4 (MH
+) = 552.35498; obtained = 552.35443 (MH+). 
 
1,4,7,10-Tetraazacyclododecane-1-(6-amino(Alloc)hexanoate benzhydryl ester)-
4,7,10-triacetate tert-butyl ester (compound 4). 1.585 g (2.87 mmol) of 1,4,7,10-
tetraazacyclododecane-1-(6-amino(Alloc)hexanoate benzhydryl  ester) were dissolved 
in 150 mL of MeCN and to this solution, 2.383 g (17.24 mmol) of potassium carbonate 
and 1.36 mL (9.21 mmol) of tert-butyl bromoacetate were added. The mixture was 
stirred overnight at room temperature, filtered under vacuum and concentrated under 
reduced pressure to give a brown oil. The oil was purified by column chromatography 
over silica gel 60 (DCM/EtOH 9:1) to afford 2.00 g (77.7%) of a yellow solid. 1H NMR 
(400 MHz, CDCl3, TMS, ): 1.35-1.65 (31H, mb, -CH2 + -CH2 + 3x3xCH3(t-Bu)), 
1.66-1.84 (2H, m, -CH2), 2.05-3.59 (24H, mb, 8xCH2(cyclen) + -CH2 + 3xCH2COR), 
3.49-3.61 (1H, m, -CH), 4.52 (2H, d, J=5.6Hz, OCH2(Alloc)), 5.17 (1H, dd, 
J1=10.4Hz, J2=1.2Hz, CH-cis(Alloc)), 5.28 (1H, dd, J1=17.2Hz, J2=1.6Hz, CH-
trans(Alloc)), 5.84-5.91 (1H, m, CH(Alloc)), 6.87 (1H, s, CH(Benzhydryl)), 7.23-7.40 
(10H, m, CH-Ph2(Benzhydryl)) ppm. 
13C NMR (100 MHz, CDCl3, TMS, ):  23.76 (-
CH2), 27.86 (3xCH3(t-Bu)), 29.62 (-CH2), 30.00 (-CH2), 40.52 (-CH2), 44.77, 47.46, 
48.16, 48.53 (CH2(cyclen)), 55.56, 55.75 (CH2COR), 61.49 (-CH), 65.30 
(OCH2(Alloc)), 78.10 (CH(Benzhydryl)), 81.73, 81.88 (CR3R’(t-Bu)), 117.41 
(CH2(Alloc)), 126.97 (CH-Ph), 127.21 (CH-Ph), 128.66 (CH-Ph), 133.02 (CH(Alloc)), 
139.17 (C-Ph), 156.36 (RCOR'(Alloc)), 172.78 (RCOR'(t-Bu)), 175.09 
(RCOR'(Benzhydryl)) ppm. HRMS (ESI+) – m/z: calculated for C49H75N5O10 (MH+) = 
894.55922; obtained = 894.55867 (MH+). 
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1,4,7,10-Tetraazacyclododecane-1-((6-amino)hexanoate benzhydryl ester)-4,7,10-
triacetate tert-butyl ester (compound 5). 965.0 mg (1.08 mmol) of 1,4,7,10-
tetraazacyclododecane-1-(6-amino(Alloc)hexanoate benzhydryl ester)-4,7,10-triacetate 
tert-butyl ester were dissolved in 50 mL of DCM and to this solution, 634.6 mg (10.77 
mmol) of borane dimethylamine complex and 1.36 mg (0,11 mmol) of 
tetrakis(triphenylphosphine)palladium(0) were added. The solution was stirred for 2 
hours at room temperature and silica gel 60 was added. The mixture was stirred for 30 
minutes at room temperature, concentrated under reduced pressure to give a brown 
powder. The powder was purified by column chromatography over silica gel 60 
(DCM/EtOH 8:2, followed by DCM/EtOH 7:3) to afford 671.5 mg (76.8%) of a brown 
solid, containing some residues of borane dimethylamine and degraded 
tetrakis(triphenylphosphine)palladium(0). The product was carried through without 
further purification. 1H NMR (400 MHz, DMSO, TMS, ): 1.32-1.85 (33H, mb, -CH2 
+ -CH2 + -CH2 + 3x3xCH3(t-Bu)),  1.90-3.62 (25H, mb, 8xCH2(cyclen) + -CH + -
CH2 + 3xCH2COR), 6.81 (1H, s, CH(Benzhydryl)), 7.25-7.45 (10H, m, CH-
Ph2(Benzhydryl)) ppm. 
13C NMR (100 MHz, DMSO, TMS, ):  23.61 (-CH2), 25.74 
(-CH2), 27.31 (-CH2), 27.53 (3xCH3(t-Bu)), 38.58 (-CH2), 44.18, 47.22, 47.78, 
52.27 (CH2(cyclen)), 55.23 (CH2COR), 60.96 (-CH), 77.56 (CH(Benzhydryl)), 81.31 
(CR3R’(t-Bu)), 126.64 (CH-Ph), 128.06 (CH-Ph), 128.76 (CH-Ph), 140.47 (C-Ph), 
172.67 (RCOR'(t-Bu)). 174.47 (RCOR'(Benzhydryl)) ppm. HRMS (ESI+) – m/z: 
calculated for C45H71N5O8 (MH
+) = 810.53809; obtained = 810.53754 (MH+). 
 
DOTA-AHA (ligand 1). 150.0 mg (0.19 mmol) of 1,4,7,10-tetraazacyclododecane-1-
((6-amino)hexanoate benzhydryl ester)-4,7,10-triacetate tert-butyl ester were dissolved 
in 3 mL of DCM and 3 mL of TFA. The solution was stirred overnight at room 
temperature, concentrated under reduced pressure to give a purple oil. The oil was 
washed 2 times with n-hexane and 2 times with water to give a yellow oil. The oil was 
dissolved in 15 ml of water and the aqueous solution was washed with 4x10 mL of 
DCM and concentrated under reduced pressure to afford 105.8 mg of a yellow solid in 
trifluoroacetate salt form. 1H NMR (400 MHz, D2O, TSP, ): 1.37-1.95 (6H, mb, -CH2 
+ -CH2 + -CH2), 2.75-4.35 (25H, mb, 8xCH2(cyclen) + -CH + -CH2 + 3xCH2COR) 
ppm. 13C NMR (100 MHz, D2O, TSP, ):  22.78 (-CH2), 26.35 (-CH2), 28.52 (-
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CH2), 38.77 (-CH2), 50.03, 51.12, 53.21, 55.14 (CH2(cyclen)), 59.81 (-CH), 63.57 
(CH2CO2H), 169.51 (RCO2H), 174.53 (RCO2H) ppm. HRMS (ESI
+) – m/z: calculated 
for C20H37N5O8 (MH
+) = 476.27204; obtained = 476.27149 (MH+). 
 
Bis(1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoate benzhydryl ester)-
4,7,10-triacetate tert-butyl ester)adipate (compound 6). 335.0 mg (413.5 mol) of 
1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoate benzhydryl ester)-4,7,10-
triacetate tert-butyl ester were dissolved in 15 mL of dry MeCN and to this solution, 
25.2 mg (172.3 mol) of adipic acid, 72 L (370.3 mol) of DIPEA, 55.9 mg (413.5 
mol) of HOBt and 157.2 mg (413.5 mol) of HATU were added. The solution was 
stirred for 72 hours at room temperature and more 55.9 mg (413.5 mol) of HOBt and 
157.2 mg (413.5 mol) of HATU were added. The solution was stirred for 48 hours at 
room temperature and more 55.9 mg (413.5 mol) of HOBt and 157.2 mg (413.5 mol) 
of HATU were added. The solution was stirred for more 48 hours at room temperature 
and concentrated under reduced pressure to give a white solid. The solid was dissolved 
in 80 mL of ethyl acetate, and the organic phase was washed with 3x40 mL of 1 M 
KHSO4 aqueous solution, 3x40 mL of 1 M NaHCO3 aqueous solution, and 3x40 mL of 
brine. The organic phases were combined, dried with anhydrous MgSO4 and 
concentrated under reduced pressure to afford 286.1 mg (95.9%) of a white solid.  1H 
NMR (400 MHz, CDCl3, TMS, ): 1.41-1.66 (66H, mb, 2x-CH2 + 2x-CH2 + 
6x3xCH3(t-Bu) + 2xCH2(linker)), 1.67-1.83 (4H, m, 2x-CH2), 1.97-3.40 (52H, mb, 
16xCH2(cyclen) + 2x-CH2 + 6xCH2COR + 2xCOCH2(linker)), 3.58-3.65 (2H, m, 2x-
CH2), 6.35 (2H, m, 2xRNHR'), 6.88 (2H, s, 2xCH(Benzhydryl)), 7.23-7.38 (20H, m, 
2xCH-Ph2(Benzhydryl)) ppm. 
13C NMR (100 MHz, CDCl3, TMS, ): 24.63 (-CH2), 
26.43 (CH2(linker)), 27.86 (3xCH3(t-Bu)), 29.21 (-CH2), 29.65 (-CH2), 35.27 
(COCH2(linker)), 38.91 (-CH2), 44.38, 47.36, 47.84, 48.21 (CH2(cyclen)), 55.59 
(CH2COR), 61.29 (-CH), 78.14 (CH(Benzhydryl)), 81.93 (CR3R’(t-Bu)), 126.95 (CH-
Ph), 128.12 (CH-Ph), 128.63 (CH-Ph), 139.24 (C-Ph), 172.87 (RCOR'(t-Bu)), 173.57 
(RCOR'), 175.26 (RCOR'(Benzhydryl)) ppm. HRMS (ESI+) – m/z: calculated for 
C96H148N10O18 (MH
+) = 1731.10849, (MH2
2+) = 866.05816; obtained = 1731.10778 
(MH+), 866.05753 (MH2+). 
 
25 
 
Bis(1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoate benzhydryl ester)-
4,7,10-triacetate tert-butyl ester)1,3-phenyldiacetate (compound 7). 425.0 mg of 
(524.6 mol) of 1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoate benzhydryl 
ester)-4,7,10-triacetate tert-butyl ester were dissolved in 20 mL of dry MeCN and to this 
solution, 42.5 mg (218.9 mol) of 1,3-phenyldiacetic acid, 92 L (524.6 mol) of 
DIPEA, 70.9 mg (524.6 mol) of HOBt and 199.5 mg (524.6 mol) of HATU were 
added. The solution was stirred for 72 hours at room temperature and more 70.9 mg 
(524.6 mol) of HOBt and 199.5 mg (524.6 mol) of HATU were added. The solution 
was stirred for 48 hours at room temperature and more 70.9 mg (524.6 mol) of HOBt 
and 199.5 mg (524.6 mol) of HATU were added. The solution was stirred for more 48 
hours at room temperature and concentrated under reduced pressure to give a yellow 
solid. The solid was dissolved in 100 mL of ethyl acetate, and the organic phase was 
washed with 3x50 mL of 1 M KHSO4 aqueous solution, 3x50 mL of 1 M NaHCO3 
aqueous solution, and 3x50 mL of brine. The organic phases were combined, dried with 
anhydrous MgSO4 and concentrated under reduced pressure to afford 334.9 mg (86.1%) 
of a yellow solid. 1H NMR (400 MHz, CDCl3, TMS, ): 1.17-1.58 (62H, mb, 2x-CH2 + 
2x-CH2 + 6x3xCH3(t-Bu)), 1.63-1.77 (4H, m, 2x-CH2), 1.94-3.39 (48H, mb, 
16xCH2(cyclen) + 2x-CH2 + 6xCH2COR), 3.49 (4H, s, 2xCH2(linker)), 3.51-3.59 (2H, 
m, 2x-CH2), 6.27 (2H, m, 2xRNHR'), 6.85 (2H, s, 2xCH(Benzhydryl)), 7.14-7.40 
(24H, mb, 2xCH-Ph2(Benzhydryl) + 4xCH(linker)) ppm. 
13C NMR (100 MHz, CDCl3, 
TMS, ): 24.14 (-CH2), 26.38 (-CH2), 27.85 (3xCH3(t-Bu)), 29.19 (-CH2), 39.11 (-
CH2), 43.51 (CH2(linker)), 44.34, 47.31, 47.81, 48.19 (CH2(cyclen)), 55.68 (CH2COR), 
61.26 (-CH), 78.10 (CH(Benzhydryl)), 81.91 (CR3R’(t-Bu)), 126.92 (CH-Ph), 127.66 
(CH-Ph(linker)), 128.13 (CH-Ph), 128.65 (CH-Ph), 128.80 (CH-Ph(linker)), 130.48 
(CH-Ph(linker)), 136.02 (C-Ph(linker)), 139.22 (C-Ph), 171.38 (RCOR'), 172.85 
(RCOR'(t-Bu)), 175.18 (RCOR'(Benzhydryl)) ppm. HRMS (ESI+) – m/z: calculated for 
C100H148N10O18 (MH2
2+) = 890.05816; obtained = 890.05753 (MH2+). 
 
Bis(DOTA-AHA)adipate (ligand 2). 279.0 mg (161.2 mol) of bis(1,4,7,10-
tetraazacyclododecane-1-((6-amino)hexanoate benzhydryl ester)-4,7,10-triacetate tert-
butyl ester)adipate were dissolved in 5 mL of DCM and 5 mL of TFA. The solution was 
stirred overnight at room temperature and concentrated under reduced pressure to give a 
purple oil. The oil was washed 2 times with n-hexane and 2 times with water to give a 
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yellow oil. The oil was dissolved in 60 mL of water and the aqueous solution was 
washed with 4x30 mL of DCM and concentrated under reduced pressure to give a white 
solid. The solid was purified by ion change column chromatography over dowex® resin 
(HO- form) to afford 245.0 mg of a white solid in hydrochloride salt form. 1H NMR 
(400 MHz, D2O, TSP, ): 1.35-2.00 (16H, mb, 2x-CH2 + 2x-CH2 + 2x-CH2 + 
2xCH2(linker)), 2.15-2.35 (4H, m, 2xCOCH2(linker)), 2.72-4.45 (54H, mb, 
16xCH2(cyclen) + 2x-CH + 2x-CH2 + 3xCH2CO2H) ppm. 13C NMR (100 MHz, D2O, 
TSP, ): 23.61 (-CH2), 24.81 (2xCH2(linker)), 26.48 (-CH2), 28.14 (-CH2), 35.39 
(COCH2(linker)), 38.15 (-CH2), 49.12, 50.57, 53.42, 54.32 (CH2(cyclen)), 60.28 (-
CH), 63.41 (CH2CO2H), 168.99 (RCO2H), 174.22 (RCO2H), 176.41 (RCOR') ppm. 
HRMS (ESI+) – m/z: calculated for C46H80N10O18 (MH+) = 1061.57303, (MNa+) = 
1083.55498, (MH2
2+) = 531.29043, (MH3
3+) = 354.52956; obtained = 1061.57249 
(MH+), 1083.55443 (MNa+), 531.29143 (MH2
2+), 354.53011 (MH3
3+). 
 
Bis(DOTA-AHA)1,3-phenyldiacetate (ligand 3). 334.0 mg (187.8 mol) of 
Bis(1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoate benzhydryl ester)-4,7,10-
triacetate tert-butyl ester)1,3-phenyldiacetate were dissolved in 5 mL of DCM and 5 mL 
of TFA. The solution was stirred overnight at room temperature and concentrated under 
reduced pressure to give a purple oil. The oil was washed 2 times with n-hexane and 2 
times with water to a give yellow oil. The oil was dissolved in 60 mL of water and the 
aqueous solution was washed with 4x30 mL of DCM, concentrated under reduced 
pressure to give a white solid. The solid was purified by ion change column 
chromatography over dowex® resin (HO- form) to afford 281.0 mg of a white solid in 
hydrochloride salt form. 1H NMR (400 MHz, D2O, TSP, ): 1.34-1.87 (16H, mb, 2x-
CH2 + 2x-CH2 + 2x-CH2), 2.75-4.29 (54H, mb, 16xCH2(cyclen) + 2x-CH + 2x-CH2 
+ 3xCH2CO2H), 3.55 (4H, s, 2xCH2(linker), 7.11-7.26 (3H, m,  2xCH(linker) + 
1xCH(linker)), 7.31-7.38 (1H, m, 1xCH(linker)) ppm. 13C NMR (100 MHz, D2O, TSP, 
):  23.64 (-CH2), 26.43 (-CH2), 28.11 (-CH2), 38.72 (-CH2), 42.32 (CH2(linker)), 
48.85, 50.55, 53.36, 54.20 (CH2(cyclen)), 60.21 (-CH), 63.36 (CH2CO2H), 127.84 
(CH(linker)), 129.76 (CH(linker)), 129.81 (CH(linker)), 135.74 (C(linker)), 168.79 
(RCO2H), 174.16 (RCO2H), 174.28 (RCOR') ppm. HRMS (ESI
+) – m/z: calculated for 
C50H80N10O18 (MH
+) = 1109.57303, (MH2
2+) = 555.29043; obtained = 1109.57248 
(MH+), 555.28988 (MH2
2+). 
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Relaxometric Studies 
 
Sample Preparation 
To an aqueous solution of the ligand, a GdCl3 solution in a 1:1 mole ratio (for 
mononuclear chelate) and in a 1:2 mole ratio (for binuclear chelates) was added 
dropwise (a slight excess of ligand was used). The pH was adjusted to around 4 with the 
addition of a 0.01 M NaOH solution and the solution was stirred for 1 hour at 60 ºC. 
The pH was adjusted to 5 with the addition of a 0.01 M NaOH solution and the solution 
was stirred overnight. The pH was then adjusted to 5.7 and the solution was 
concentrated under reduced pressure. 
In all cases, to the final solution, H2
17O (17O = 20.2 %) was added to obtain a final 
2% 17O-enrichment in order to improve the sensitivity of 17O NMR measurements. The 
absence of free metal was checked with xylenol orange.[41] The final concentration of 
Gd(III) was determined by susceptibility measurements in the presence of t-butanol.[42] 
The Gd(III) concentration in the samples were: monomer chelate ≈ 20 mM and 
binuclear chelates ≈ 12 mM. 
 
1H NMRD 
Sample tubes with an outer diameter of 5 mm were used for measurements. The proton 
longitudinal relaxation rates (1/T1) for the water nuclear magnetic relaxation dispersion 
profiles (NMRD) were measured at 0.47 T (1H Larmor frequency: 20 MHz), 0.70 T 
(30 MHz), 0.94 T (40 MHz), 1.41 T (60 MHz), 2.35 T (100 MHz), 4.7 T (200 MHz) 
and 9.4 T (400 MHz). The longitudinal relaxation rates of six chelates with known 
concentration were measured at two different temperatures (25 and 37 ºC). Acidified 
water (pH = 3.0) was used as an external reference. The relaxivities r1 (mM
-1.s-1) were 
calculated using equation 1 using diamagnetic relaxation contributions 1/T1(d) of 0.31 s
-1 
(400 MHz) / 0.40 s-1 (20 MHz) for 25 ºC and 0.25 s-1 (400 MHz) / 0.29 s-1 (20 MHz) for 
37 ºC, respectively. 
 
𝑟1 =
1
[𝐺𝑑3+]
(
1
𝑇1
−
1
𝑇1(d)
) , with [Gd3+] in mM (8) 
 
For full equations see Supplementary Information. 
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17O NMR 
The samples were sealed in glass spheres adapted for 10 mm NMR tubes, in order to 
avoid susceptibility corrections to the chemical shifts.[43] Variable-temperature 17O 
measurements were performed at 9.4 T (17O Larmor frequency: 54.3 MHz). The 
longitudinal (1/T1) and transverse (1/T2) relaxation rates were measured using the 
inversion-recovery[44] and the Carr–Purcell–Meiboom–Gill[45] pulse sequences, 
respectively, and chemical shifts () were measured at 12 different temperatures in the 
range from 5 to 65 °C. The reduced relaxation rates T1r and T2r and the reduced 
chemical shift differences r, with respect to a pH 3.0 water reference (2% 17O-
enrichment), were calculated using equations 2 to 4. The number of water molecules in 
the inner sphere of the complex q was fixed to one. 
 
1
𝑇ir
=
1
𝑃𝑀
(
1
𝑇i
−
1
𝑇i
ref) , where i = 1, 2 (9) 
 
∆𝜔𝑟 =
1
𝑃𝑀
(𝜔 − 𝜔ref) (10) 
 
𝑃M =
𝑞[M𝑛+]
55.56
 (11) 
 
For full equations see Supplementary Information (SI) 
 
Data Analysis 
For fits of the 1H NMRD and 17O NMR data, a Solomon–Bloembergen-based theory 
was used[43b, 46]  supplemented with the Lipari–Szabo free-model approach for the 
internal rotation.[23a, 23b] The simultaneous fits were performed using 
Visualiseur/Optimiseur[47] running on a MATLAB® 8.0 (R2012b) platform. 
 
DEER Studies 
 
Sample Preparation 
The chelates were prepared using the same method previously used for the relaxometric 
studies. 
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For the measurements, solutions were prepared by dissolving 600 mol of the chelate in 
2 ml of H2O and then the mixture was centrifuged. A 200 L aliquot of supernatant was 
collected and mixed with a 200 L aliquot of glycerol to obtain the final solution. 
 
Measurements 
The Gd(III)-Gd(III) distance measurements were performed with the 4 pulse double 
electron-electron resonance (DEER) experiment[30b, 33a] at Q band on a home-built high 
microwave power spectrometer[39] equipped with a rectangular resonator 
accommodating for 3 mm outer diameter samples.[40] The measurements were 
performed at 10 K and the temperature was set and stabilized with a He-flow cryostat 
Oxford Instruments ER 4118 CF. 
In the DEER pulse sequence all microwave pulses were set to duration of 12 ns, first 
inter-pulse interval of 400 ns and the length of the DEER time trace of 3 s was set. The 
frequency difference between pump and detection pulses was set to 300 MHz. 
 
Data Analysis 
The DEER time traces were analyzed with the DeerAnalysis software.[35] A model free 
fit with Tikhonov regularization was performed in each case. 
 
Molecular Modelling 
The molecular modelling has been performed Scigress (Fujitsu) Version 3.1.0. 
Structures are taken from MD conformational searches and energy minimized, both in 
vacuum. The force-field used is MM3; Gd(III) has been replaced by Y(III) which has 
approximately the same ionic radius. 
 
Abbreviations 
 
Alloc Allyloxycarbonyl 
(Bis(DOTA-AHA)1,3-
phenyldiacetate) 
Bis(1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoic)-
4,7,10-triacetic acid)1,3-phenyldiacetate  
(Bis(DOTA-AHA)1,3-
phenyldiacetate) 
Bis(1,4,7,10-tetraazacyclododecane-1-((6-amino)hexanoic)-
4,7,10-triacetic acid)1,3-phenyldiacetate  
Boc tert-Butyloxycarbonyl 
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CA Contrast agent 
Cyclen 1,4,7,10-tetraazacyclododecane 
DCM Dichloromethane 
DDM Diphenyldiazomethane 
DEER Double electron-electron resonance 
DIPEA N,N-Diisopropylethylamine 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
DOTA-AHA 1,4,7,10-Tetraazacyclododecane-1-((6-amino)hexanoic)-
4,7,10-triacetic acid 
DOTA 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DO3A 1,4,7,10-Tetraazacyclododecane-1,4,7-triaacetic acid 
EPR Electron paramagnetic resonance 
ESI Electrospray ionization 
EtOH Ethanol 
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HMBC Heteronuclear multiple bond correlation 
HOBt 1-Hydroxybenzotriazole 
HRMS High resolution mass spectrometry 
Lys Lysine 
MeCN Acetonitrile 
MRI Magnetic resonance imaging 
NMR Nuclear magnetic resonance 
NMRD Nuclear magnetic relaxation dispersion 
Pd/C Palladium on carbon 
SBM Solomon-Bloembergen-Morgan theory 
SD Standard deviation 
SDSL Site directed spin labelling 
TFA Trifluoroacetic acid 
TLC Thin layer chromatography 
TMS Tetramethylsilane 
TSP 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt 
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t-Bu tert-Butyl 
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